Which one is the best cardiac pump?

Tags: biotrue contact solution, cardiac solutions, silverstreak solutions

A new medical device developed by a German company can help save lives when a heart attack hits, thanks to a unique combination of the heart’s natural chemical reactions and the use of a patented technology called bio-toxicant therapy.

A study published in the journal Cell on Wednesday shows that the new technology is effective in reducing the symptoms of multiple-organ failure, as well as the severity of infections and strokes.

The technology is currently in clinical trials, and it will be tested on patients in the next few months.

Bio-toxics have previously been used to treat heart attacks in humans, and they have shown to be effective in treating other diseases including Parkinson’s disease.

Bioethics expert Richard Davidson said the technology could offer a new approach to treating many illnesses, including a stroke, heart attack and other cardiovascular conditions.

“The idea that you can have this one drug and it might be effective and you could reduce the severity and the symptoms is a very exciting thing,” he told The Huffington Post UK.

“It opens up the possibility that we could do a lot more.”

The team from the University of Würzburg in Germany and the German Aerospace Center has been working on this idea for more than a decade.

The first batch of the device was developed to be a type of cardiac pump for the heart, and was then developed to work in the lungs.

It uses a mixture of two compounds, carbon dioxide and oxygen, to help control the heart and lungs, as they pump out oxygen and carbon dioxide.

The team then designed the new device to incorporate a unique chemical reaction that is activated when a patient’s blood contains a chemical called biotrue, which binds to the molecule in the body and inhibits it from binding to other molecules.

The chemical is then released from the pump and the blood stops being able to flow through the body.

In a typical test tube, the researchers used a standard tube to inject the biotru into a patient, but they have now developed a device that can be inserted directly into the heart to see if it can help.

The new device is now being tested on a group of patients at the University Hospital of Graz in Austria, where they have been treating patients for multiple organ failure.

It has shown promising results.

“We have found the patients with a heart failure who are taking this medication in this group are actually having a better outcome than the control group,” said Dr Philippa Fischbein, a professor of medicine at the university and an expert in bioethics.

“The patients who were receiving an average of one drug per day, they did not show any improvement.”

She added that it is very difficult to know if the drug is working on the patient’s heart, as the drugs used in this study are not well studied in humans.

However, she said it was possible the therapy might improve other symptoms such as fatigue, heart palpitations and headaches.

The researchers say the results of their research should be used as a starting point to design more efficient treatments for people who are currently not being treated with other medications.

The drug is currently undergoing clinical trials in Austria.

The device is currently being tested in the University hospital of Gaz, Austria, which is also known as the University Hospitals of Vienna, and has been used successfully in a trial in a different hospital in Austria in 2014.

A spokesperson for the university hospital said that the device is in clinical trial in patients aged between 25 and 54 and is currently under consideration for sale in Europe.

The University of Gazzalotta, in Switzerland, is also working on a similar device.